RecruitingPhase 2NCT05967182

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Hop Tran Cao, MD, M.D
M.D. Anderson Cancer Center
Intervention
Pembrolizumab(drug)
Enrollment
24 target
Eligibility
18 years · All sexes
Timeline
20242029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05967182 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials